Scynexis (SCYX) Other Non Operating Income (2014 - 2026)

Scynexis' (SCYX) quarterly Other Non Operating Income came in at $354000.0 in Q1 2026, up 1164.29% on a QoQ basis from $28000.0 in Q2 2024.

Scynexis (SCYX) Other Non Operating Income (2014 - 2026) Analysis & Trends

Scynexis (SCYX) has 8 years of Other Non Operating Income data on file, last reported at $354000.0 in Q1 2026.

Quarterly Other Non Operating Income changed N/A year-over-year to $354000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $354000.0 (up 1164.29% YoY) and the FY2024 annual result came in at $196000.0, up 853.85% from the prior year.
Other Non Operating Income grew to $354000.0 in Q1 2026, from $28000.0 in the prior quarter.
In the past five years, Other Non Operating Income ranged from a high of $354000.0 in Q1 2026 to a low of -$1.1 million in Q4 2022.
A 4-year average of -$62200.0 and a median of $35000.0 in 2023 frame the typical range for Other Non Operating Income.
The widest YoY moves for Other Non Operating Income: up 533.33% in 2023, down 3223.08% in 2023.
Tracing SCYX's Other Non Operating Income over 4 years: stood at -$1.1 million in 2022, then surged by 113.97% to $156000.0 in 2023, then slumped by 82.05% to $28000.0 in 2024, then surged by 1164.29% to $354000.0 in 2026.
The last three Other Non Operating Income figures came in at $354000.0 (Q1 2026), $28000.0 (Q2 2024), and $168000.0 (Q1 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.76 Bn	42.79 Bn	-
2	Teva Pharmaceutical Industries	43.38 Bn	39.73 Bn	2.15 Bn
3	Zoetis	31.61 Bn	29.93 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.64 Bn	22.84 Bn	5.10 Bn
5	United Therapeutics	22.20 Bn	19.54 Bn	683.80 Mn
6	Viatris	18.82 Bn	17.93 Bn	1.46 Bn
7	Neurocrine Biosciences	15.67 Bn	15.28 Bn	935.80 Mn
8	Elanco Animal Health	12.11 Bn	11.58 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-
10	Scynexis	60.95 Mn	-53.74 Mn	-

Download Data